AN ARTICLE FROM IMMUNOSTEP
Microvesicles vs. Exosomes: Why Differentiate Them Into Biomarkers?
In the recent blog post titled “Microvesicles vs. Exosomes: Why Differentiate Them Into Biomarkers?”, Immunostep introduced a critical perspective on the evolving field of extracellular vesicle (EV) research. While exosomes have traditionally dominated the spotlight as clinical biomarker candidates, this post highlights their often-overlooked counterparts—microvesicles (or ectosomes)—and explains why distinguishing between the two is no longer just a technical detail, but a necessity for precision medicine.
ABOUT THE SUPPLIER
Spain-Based Leader in Exosome Research and Flow Cytometry Solutions
As one of the leading providers of technologies, tools, and services for bioscience and biopharmaceutical manufacturing, Immunostep offer a wide range of assays, kits and solutions for Flow Cytometry.
In 2019 Immunostep R&D team recognized the great potential of exosomes and since then they have been working on the development of the best methods for detection, quantification, isolation, characterisation and immunophenotyping of extracellular vesicles (EVs). Featured products include Exosome FACS capture and detection kit, the ExoStep, and exosome isolation products.
Immunostep works in accordance with the standard UNE-EN ISO 13485: 2018 (EN ISO 13485: 2016 & ISO 13485: 2016).
